La vendita allo scoperto per Evofem Biosciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Evofem Biosciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Evofem Biosciences (OTC:EVFM) Azioni, Report sulle vendite allo scoperto

Evofem Biosciences

Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.

EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc.

Evofem Biosciences Inc

Golub Capital BDC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBDC#NASDAQ">GBDC</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.41 by 4.88 percent. This is a 23.53 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $213.89 million which missed the analyst consensus estimate of $224.39 million by 4.68 percent. This is a 30.24 percent increase over sales of $164.23 million the same period last year.

Earnings

Earnings Misses

News

GBDC

Golub Capital BDC Q2 Adj. EPS $0.39 Misses $0.41 Estimate, Sales $213.89M Miss $224.39M Estimate

AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.25) by 2.4 percent. This is a 21.95 percent increase over losses of $(1.64) per share from the same period last year. The company reported quarterly sales of $27.77 million which beat the analyst consensus estimate of $15.27 million by 81.82 percent. This is a 286.84 percent increase over sales of $7.18 million the same period last year.

Earnings Beats

ANAB

AnaptysBio Q1 EPS $(1.28) Misses $(1.25) Estimate, Sales $27.77M Beat $15.27M Estimate

FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) affirms FY2025 sales outlook from $530.00 million-$595.00 million to $530.00 million-$595.00 million vs $567.88 million estimate.

Guidance

RAIL

FreightCar America Affirms FY2025 Sales Guidance of $530.00M-$595.00M vs $567.88M Est

Titan America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTAM#NYSE">TTAM</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.20 by 5 percent. This is a 5 percent decrease over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $392.44 million which missed the analyst consensus estimate of $400.33 million by 1.97 percent.

TTAM

Titan America Q1 EPS $0.19 Misses $0.20 Estimate, Sales $392.44M Miss $400.33M Estimate

FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.08 by 37.5 percent. This is a 150 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $96.29 million which missed the analyst consensus estimate of $104.33 million by 7.70 percent. This is a 40.21 percent decrease over sales of $161.06 million the same period last year.

FreightCar America Q1 Adj. EPS $0.05 Misses $0.08 Estimate, Sales $96.29M Miss $104.33M Estimate

Diversified Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHC#NASDAQ">DHC</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 500 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $386.86 million which beat the analyst consensus estimate of $383.17 million by 0.97 percent. This is a 4.34 percent increase over sales of $370.78 million the same period last year.

Diversified Healthcare Q1 FFO $0.06 Beats $0.03 Estimate, Sales $386.86M Beat $383.17M Estimate

Great Elm Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GECC#NASDAQ">GECC</a>) reported quarterly earnings of $0.40 per share which beat the analyst consensus estimate of $0.38 by 5.26 percent. This is a 8.11 percent increase over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $12.50 million which beat the analyst consensus estimate of $12.11 million by 3.22 percent. This is a 40.31 percent increase over sales of $8.91 million the same period last year.

GECC

Great Elm Capital Q1 EPS $0.40 Beats $0.38 Estimate, Sales $12.50M Beat $12.11M Estimate

RBC Capital Markets analyst Biraj Borkhataria reiterated the Outperform rating on Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) following <a href="https://www.benzinga.com/quote/SHEL/analyst-ratings" target="_blank" rel="noreferrer noopener">Friday&#8217;s first-quarter results</a>.
The company reported revenue of $69.234 billion, which missed the consensus of $79.13 billion. Adjusted earnings per ADS of $1.84 exceeded <a href="https://www.benzinga.com/25/05/45168189/shells-q1-profit-surges-52-announces-35-billion-buyback-more" target="_blank" rel="noreferrer noopener">the consensus of $1.65</a>.
The company expects 2025 cash capital&nbsp;expenditures&nbsp;to be&nbsp;&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$20 billion—$22 billion</a>.
For the&nbsp;second quarter, it expects&nbsp;production at Integrated Gas of approximately&nbsp;890 – 950 thousand boe/d and Upstream of about 1,560 – 1,760 thousand boe/d.
Shell management commentary offers a sense of stability regarding the execution of strategic objectives and shareholder distributions, the analyst says.
A robust balance sheet provides confidence that the company will likely maintain its share repurchase program, Borkhataria says.
This consistent buyback activity should contribute to accelerated earnings per share growth over the long term, adds the analyst.
Going forward, the analyst expects Shell&#8217;s planned divestments in its upstream operations in Nigeria to lead to further cost reductions. 
Additionally, the anticipated sale of the Chemicals division should eliminate a currently unprofitable asset from its financial statements, adds the analyst.
Borkhataria writes that Shell&#8217;s marketing business&#8217;s improving underlying performance is a positive sign, particularly given its weaker profitability in recent years.
The analyst lowered the 2026 estimates to reflect prevailing broader industry trends while remaining somewhat cautious regarding the Chemicals segment.
Overall, Borkhataria raised EPS estimates to $3.28 (from $3.04) for 2025 and $3.74 (from $3.72) for 2026.
Investors can gain exposure to Shell via&nbsp;Precidian ETFs Trust Shell plc ADRhedged&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEH#NYSE">SHEH</a>) and&nbsp;Abacus FCF Real Assets Leaders ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ABLD#BATS">ABLD</a>).
Price Action: SHEL shares are down 1.77% at $65.46 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/05/45169718/equinor-offloads-major-stake-in-brazilian-oil-field-in-3-35-billion-exit" target="_blank" rel="noreferrer noopener">Equinor Offloads Major Stake in Brazilian Oil Field In $3.35 Billion Exit</a></li>
</ul>
Image: Shutterstock

Large Cap

Reiteration

ABLD

AstraZeneca PLC ADRhedged Shell plc ADRhedged

SHEH

SHEL

Shell Chemical Division Sale To Improve Bottom Line: Analyst

<a href="https://www.bloomberg.com/news/articles/2025-05-05/gamestop-sells-its-canadian-chain-of-stores-to-toy-entrepreneur?taid=68191dae7e031100014c868b&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter" title="https://www.bloomberg.com/news/articles/2025-05-05/gamestop-sells-its-canadian-chain-of-stores-to-toy-entrepreneur?taid=68191dae7e031100014c868b&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter">https://www.bloomberg.com/news/articles/2025-05-05/gamestop-sells-its-canadian-chain-of-stores-to-toy-entrepreneur?taid=68191dae7e031100014c868b&amp;utm_campaign=trueanthem&amp;utm_medium=social&amp;utm_source=twitter</a>

Asset Sales

'GameStop Sells Its Canadian Chain of Stores to Toy Entrepreneur, Stephan Tetrault' - Bloomberg News

TALO

Talos Energy Q1 Adj. EPS $(0.06) Beats $(0.09) Estimate, Sales $513.06M Beat $498.89M Estimate

Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) widens FY2025 sales outlook from $1.30 billion-$1.40 billion to $1.25 billion-$1.40 billion vs $1.36 billion estimate.

NGVT

Ingevity Widens FY2025 Sales Guidance from $1.30B-$1.40B to $1.25B-$1.40B vs $1.36B Est

Playa Hotels &amp; Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.36 by 2.78 percent. This is a 7.5 percent decrease over earnings of $0.40 per share from the same period last year. The company reported quarterly sales of $267.29 million which beat the analyst consensus estimate of $266.84 million by 0.17 percent. This is a 11.09 percent decrease over sales of $300.63 million the same period last year.

PLYA

Playa Hotels & Resorts Q1 Adj. EPS $0.37 Beats $0.36 Estimate, Sales $267.29M Beat $266.84M Estimate

Atlas Energy Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AESI#NYSE">AESI</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.16 by 93.75 percent. This is a 96.15 percent decrease over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $297.59 million which beat the analyst consensus estimate of $290.07 million by 2.59 percent. This is a 54.46 percent increase over sales of $192.67 million the same period last year.

AESI

Atlas Energy Solutions Q1 EPS $0.01 Misses $0.16 Estimate, Sales $297.59M Beat $290.07M Estimate

New Mountain Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMFC#NASDAQ">NMFC</a>) reported quarterly earnings of $0.32 per share which met the analyst consensus estimate. This is a 11.11 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $85.66 million which missed the analyst consensus estimate of $86.65 million by 1.14 percent. This is a 5.40 percent decrease over sales of $90.56 million the same period last year.

NMFC

New Mountain Finance Q1 Net Investment Income $0.32, Inline, Sales $85.66M Miss $86.65M Estimate

Ingevity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.74 by 33.78 percent. This is a 90.38 percent increase over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $284.00 million which missed the analyst consensus estimate of $285.47 million by 0.51 percent. This is a 16.50 percent decrease over sales of $340.10 million the same period last year.

Ingevity Q1 Adj. EPS $0.99 Beats $0.74 Estimate, Sales $284.00M Miss $285.47M Estimate

Primoris Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRIM#NASDAQ">PRIM</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.66 by 48.48 percent. This is a 108.51 percent increase over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.49 billion by 10.58 percent. This is a 16.63 percent increase over sales of $1.41 billion the same period last year.

PRIM

Primoris Services Q1 Adj. EPS $0.98 Beats $0.66 Estimate, Sales $1.65B Beat $1.49B Estimate

Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is looking for Q4 Adj EPS of $2.50-$2.70 vs $2.69 analyst estimate. sees sales of $860.000 million-$900.000 million vs $888.62 million analyst estimate.

Fabrinet Sees Q4 Adj EPS $2.50-$2.70 vs $2.69 Est; Sees Sales $860.000M-$900.000M vs $888.62M Est

Certara (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERT#NASDAQ">CERT</a>) affirms FY2025 Adj EPS guidance from $0.42-$0.46 to $0.42-$0.46 vs $0.45 analyst estimate. Affirms FY2025 sales outlook from $415.00 million-$425.00 million to $415.00 million-$425.00 million vs $420.67 million estimate.

CERT

Certara Affirms FY2025 Adj EPS Guidance of $0.42-$0.46 vs $0.45 Est; Affirms FY2025 Sales Guidance of $415.00M-$425.00M vs $420.67M Est

Spruce Power Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) ("Spruce" or the "Company") today announced that Sarah Wells, Chief Financial Officer ("CFO"), has resigned, effective May 14, 2025, to pursue other opportunities. Spruce expects to appoint an interim CFO prior to Wells departing. The Company is undertaking a search to fill the CFO position on a permanent basis.

Management

Spruce Power Holding Corporation Class A Common Stock

SPRU

Spruce Power Holding CFO Sarah Wells Resigns, Effective May 14, 2025

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) raises FY2025 GAAP EPS guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 analyst estimate..

Clorox Raises FY2025 GAAP EPS Guidance from $5.52-$5.92 to $5.73-$6.13 vs $5.64 Est

Press Releases

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Small Cap

Evofem Biosciences to Present at Emerging Growth Conference

Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream

Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Comments

Evofem Biosciences

Vendite allo scoperto

Evofem Biosciences (OTC:EVFM) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO